The influence of isoprivet on neutrophil secretory action in the course of BRD in calves

• Autorzy: Wessely-Szponder J. , Kloc K.
• Języki publikacji: EN

Abstrakty

EN

Słowa kluczowe

EN

neutrophil; elastase; bovine respiratory disease; multifactorial disease; cattle farm; lung tissue; isoprinosine; proteolytic enzyme; myeloperoxidase

• Wydawca: -
• Czasopismo: Electronic Journal of Polish Agricultural Universities. Series Veterinary Medicine
• Rocznik: 2010
• Tom: 13
• Numer: 4
• Opis fizyczny: http://www.ejpau.media.pl/volume13/issue4/art-05.html

Twórcy

autor

Wessely-Szponder J.

• Department of Pathophysiology, Faculty of Veterinary Medicine, Agricultural University in Lublin, Akademicka 12, 20-033 Lublin, Poland

autor

Kloc K.

Bibliografia

• 1. Barnes D.M., Camplejohn R.R., 1996. P53, apoptosis and breast cancer. J. Mammary Gland Biol. Neoplasia, 1, 163–175.
• 2. Baudino T.A., Cleveland J.L., 2001. The Max network gone Mad. Mol. Cell. Biol., 21, 691–702.
• 3. Beaudry G.A., Bertelsen A.H., Sherman M.I., 1996. Therapeutic targeting of the p53 tumor suppressor gene. Current opinion in biotechnology, 7, 592–600.
• 4. Bertheau P., Plassa L.F., Espie M., Turpin E., de Roquancourt A., Marty M., Lerebours F., Beuzard Y., Janin A., de The H., 2002. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet, 360, 852–854.
• 5. Bertheau P. Turpin E, Rickman D.S., Espie M., de Reynies A., Feugeas J.P., Plassa L.F., Soliman H., Varna M., de Roquancourt A., Lehmann J., Beuzard Y., Marty M., Misset J.L., Janin A., de The H., 2007. Exquisite senstitivity of TP53 mutant and basal breast cancer to a dose-dense epirubicin-cyclophosphamide regimen. PloS Med, 4, 585–594.
• 6. Bertheau P., Espie M., Turpin E., Lehmann J., Plassa L.F., Varna M., Janin A., de The H., 2008. TP53 status and response to chemotherapy in breast cancer. Pathobiology, 75, 132–130.
• 7. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B., 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest., 104, 263–269.
• 8. Cadwell C., Zambetti G.P., 2001. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene, 277, 15–30.
• 9. Chen C.J., Oliner J.D., Zhan Q., Fornace A.J., Vogelstein B., Kastan M.B., 1994. Interaction between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci USA, 91, 2684–2688.
• 10. Chu L.L., Rutteman G.R., Kong J.M., Ghahremani M., Schmeing M., Misdorp W., van Garderen E., Pelletier J., 1998. Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res. Treat., 50, 11–25.
• 11. Chumakov P.M., 2007. Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc), 72, 1399–1421.
• 12. Danilova N., Sakamoto K.M., Lin S., 2008. Role of p53 family in birth defects: lessons from zebrafish. Birth Defects Research, 84, 215–227.
• 13. Dominguez-Sola D., Ying C.Y., Grandori C., Ruggiero L., Chen B., Li M., Galloway D.A., Gu W., Gautier J., Dalla-Favera R., 2007. Non-transcriptional control of DNA replication by c-Myc. Nature 448, 445–451.
• 14. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery Jr. C.A., Butel J.S., Bradley A., 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215–221.
• 15. Finlay C.A., Hinds P.W., Levine A.J., 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57, 1083–1093.
• 16. Gamblin R.M., Sagartz J.E., Couto C.G., 1997. Overespression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. A. J. Vet. Res., 58, 857–863.
• 17. Garte S.J., 1993. The c-myc oncogene in tumor progression. Crit. Rev. Oncolog., 4, 435–449.
• 18. Gasco M., Shami S., Crook T., 2002. The p53 pathway in breast cancer. Breast Cancer Res., 4, 70–76.
• 19. Haga S., Nakayama M., Tatsumi K., Maeda M., Imai S., Umesako S., Yamamoto H., Hilgers J., Sarkar N.H., 2001. Overexpression of the p53 gene product in canine mammary tumors. Oncol. Rep., 8, 1215–1219.
• 20. Harris C.C., 1993. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science, 262, 1980–1981.
• 21. Heidenberg H.B., Bauer J.J., McLeod D.G., Moul J.W., Srivastava S., 1996. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology, 48, 971–979.
• 22. Inoue M., Shiramizu K., 1999. Immunohistochemical detection of p53 and c-myc proteins in canine mammary tumours. J. Comp. Pathol., 120, 169–175.
• 23. Johnson A.S., Couto C.G., Weghorst C.M., 1998. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis, 19, 213–217.
• 24. Jones S.N., Roe A.E., Donehower L.A., Bradley A., 1995. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature, 378, 206–208.
• 25. Jones S.N., Sands A.T., Hancock A.R., Vogel H., Donehower L.A., Linke S.P., Wahl G.M., Bradley A., 1996. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of mdm2. Prc. Natl. Acad. Sci. USA, 93, 14106–14111.
• 26. Kanaya N., Okuda M., Toyama N., Oikawa T., Inokuma H., Morimoto M., Hayashi T., Une S., Nakaichi M., Taura Y., Tsujimoto H., Onishi T., 2002. Detection of the anti-p53 antibodies in dogs with tumors. J. Vet. Med. Sci., 64, 973–979.
• 27. Kastan M.B., Onyekwere O., Sidransky D., 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304–6311.
• 28. Kuerbitz S.J., Plunkett B.S., Walsh W.V., 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89, 7491–7495.
• 29. Lane D.P., Crawford L.V., 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261–263.
• 30. Lane D.P., 1992. p53, guardian of the genome. Nature, 385, 15–16.
• 31. Lee Ch.H., Kim W.H., Lim J.H., Kang M.S., Kim D.J., Kweon O.K., 2004. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J.Vet. Sci., 5, 63–69.
• 32. Levy N., Yonish-Rouach E., Oren M., Kimchi A., 1993. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol. Cell. Biol., 13, 7942–7952.
• 33. LiQ., Falsey R.R., Gaitonde S., Sotello V., Kislin K., Martinez J.D., 2007. Genetic analysis of p53 nuclear importation. Oncogene, 26, 7885–7895.
• 34. Libermann T.A., Zerbini L.F., 2006. Targeting transcription factors for cancer gene therapy. Curr. Gene Ther. , 6, 17–33.
• 35. Linzer D.I.H., Levine A.J., 1979. Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and unifected embryonal carcinoma cells. Cell, 17, 43–52.
• 36. Lozano G., Liu G., 1998. Mouse models dissect the role of p53 in cancer and development. Semin. Cancer Biol., 8, 337–344.
• 37. Lowe S.W., Ruley H.E., Jacks T., Housman D.E., 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957–967.
• 38. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T., 1994. p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807–810.
• 39. MacEwen E. G., Khanna C., Radinsky R., 2001. Cancer biology and metastasis w Small Animal Clinical Oncology, red. Withrow S.J., MacEwen E.G., W.B. Saunders Company, Philadelphia.
• 40. Madej J.A., Klimentowski S., Kuźmak J., 2001. Role of p53 gene in pathogenesis of bovine leukemia (BLV-induced). Pol. J. Vet. Sci., 4, 225–230.
• 41. Malkin D., Li F.P., Strong L.C., Fraumeni Jr. J.F., Nelson C.E., Kim D.H., Hassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., Friend S.H., 1990. Germ line mutations in a familiar syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233–1238.
• 42. McCormick F., 2001. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer., 1, 130–141.
• 43. Michael D., Oren M., 2002. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev., 12, 53–59.
• 44. Miyashita T., Krajewski S., Krajewski M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C., 1994. Tumor suppressor p53 is regulator of bcl-2 and bax gene expression in vitro and in vivo. Ocogene, 9, 1799–1805.
• 45. Moberg K.H., Tyndall W.A., Hall D.J., 1992. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line. J. Cell Biochem., 49, 208–215.
• 46. Moll U.M., Ostermeyer A.G., Ahomadegbe J.CH., Mathieu M.CH., Riou G., 1995. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies. Hum. Pathol., 26, 1293–1301.
• 47. Moll U.M, Schramm L.M., 1998. p53-an acrobat in tumorigenesis. Critical Reviews in Oral Biology & Medicine, 9, 23–37.
• 48. Montes de Osca Luna R., Wagner D.S., Lozano G., 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 378, 203–206.
• 49. Muto T., Wakui S., Takahashi H., Maekawa S., Masaoka T., Ushigome S., Furusato M., 2000. p53 gene mutation occuring in spontaneous benign and malignant mammary tumors of the dog. Vet. Pathol., 37, 248–253.
• 50. Nicol C.J., Harrison M.L., Laposa R.R., Gimelshtein IL., Wells PG., 1995. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat. Genet., 10, 181–187.
• 51. Norimura T., Nomoto S., KatsukiM., Gondo Y., Kondo S., 1996. p53 – dependent apoptosis suppresses radiation-induced teratogenesis. Nat. Med., 2, 577–580.
• 52. Oren M., 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem., 274, 36031–36034.
• 53. Ribeiro-Silva A., Ramalho L. N., Garcia S.B., Zucoloto S., 2003. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch. Pathol. Lab. Med., 127, 336–338.
• 54. Royds J.A., Jacopetta B., 2006. p53 and the disease: when the guardian angel fails. Cell Death Differ., 13, 1017–1026.
• 55. Ryan K.M., Phillips A.C., Vousden K.H., 2001. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell. Biol., 13, 332–337.
• 56. Scoumanne A., Chen X., 2008. Protein methylation: a new mechanism of p53 tumor suppressor regulation. Histol. Histopathol., 23, 1143–1149.
• 57. Schafer K.A., Kelly G., Schrader R., Griffith W.C., Muggenburg B.A., Tierney L.A., Lechner J.F., Janovitz E.B., Hahn F.F., 1998. A canine model of familiar mammary gland neoplasia. Vet. Pathol., 35, 168–177.
• 58. Sentman C.L., Shutter J.R., Hockenbery D., Kanagawa O., Korsmeyer S.J., 1991. Bcl-2 inhibits multiple form of apoptosis but not negative selection in thymocytes. Cell, 67, 879–888.
• 59. Setoguchi A., Sakai T., Okuda M., Minehata K., Yazawa M., Ishizaka T., Watari T., Nishimura R., Sasaki N., Hasegawa A., Tsujimoto H., 2001. Aberrations of the p53 tumor suppressor gene in various tumors in dog. Am. J. Vet. Res., 62, 433–439.
• 60. Sikora E., 1993. Nieśmiertelność, starzenie i śmierć komórek. Rola protoonkogenów, onkogenów i antyonkogenów [Immortality, ageing and death of the cell. Function of protooonkogenes, onkogenes and antyonkogenes]. Postępy biochemii, 39, 212–219 [in Polish].
• 61. Sharpless N.E., DePinho R.A., 2002. p53: goog cop / bad cop. Cell, 110, 9–12.
• 62. Strasser A., Harris A.W., Cory S., 1991. Bcl-2 transgene inhibits T cell death and perturbs thymic self-cencorship. Cell, 67, 889–899.
• 63. Thottassery J.V., Zambetti G.P., Arimor K., Schuetz E.G., Schuetz J.D., 1997. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA, 94, 11037–11042.
• 64. Wakui S., Muto T., Yokoo K., Takahashi H., Masaoka T., Hano H., Furusato M., 2001. Prognostic status of the p53 gene mutation in canine mammary carcinoma. Anticancer Res., 21, 611–616
• 65. Weinberg R.A., 1994. Oncogenes and tumor suppressor genes. Cancer J. Clin., 44, 160–170.
• 66. Williams G.T., 1991. Programmed cell death: apoptosis and oncogenesis. Cell, 65, 1097–1098.
• 67. Winiarczyk S., Zielewicz J., Łopuszyński W., Grądzki Z., Nozdryn-Płotnicki Z., Lechowski R., Jagielski D., 2001. Wykazanie ekspresji mRNA genu c-myc w chłoniakach u psów [Demonstration of the expression of c-myc mRNA in lymphangioma in dogs]. Medycyna Wet., 57, 736–740 [in Polish].
• 68. Van Leeuwen I.S., Hellmen E., Cornelisee C.J., Van den Burgh B., Rutteman G.R., 1996. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in dog. Anticancer Res., 16, 3737–3744.
• 69. Veis D.J., Sorenson C.M., Shutter J.R., Korsmeyer S.J., 1993. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair. Cell, 75, 229–240.
• 70. Veldhoen N., Stewart J., brown R., Milner J., 1998. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene, 16, 249–255.
• 71. Veldhoen N., Watterson J., Brash M., Milner J., 1999. Identification of tumour-associated and germ line p53 mutations in canine mammary cancer. Br. J. Cancer, 81, 409–415.
• 72. Vogelstein B., Lane D., Levine A.J., 2000. Surfing the p53 network. Nature, 408, 307–310.
• 73. Vogelstein B., Kinzler K.W., 1992. p53 function and dysfunction. Cell, 70, 523–526.
• 74. Vousden K.H., 2000. p53 death star. Cell, 103, 691–694.
• 75. Yap D.B.S., Hsieh J.K., Lu X., 2000. Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation. J. Biol. Chem., 275, 37296–37302.
• 76. Yonish-Rouach E., Resnitzky D., Lotem J., 1991. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature, 352, 345–347.
• 77. Zambetti D.R., Levine A.J., 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7, 855–865.